Fair Value Calculator Fair Value Calculator
EN DE

2251 (2251) Fair Value & Analysis

Healthcare · Market cap HK$1.1B

2 2251 2251 · HK
PriceHK$10.96
Fair ValueHK$6.88
Upside-37.2%
Quality56/100
Watch 2251 for free — get notified when fair value or trend changes. Watch for free
Evidence: Low Range HK$4.54 – HK$8.60

Fair value as of: Jul 2, 2026

From 1 valuation models · updated today

Share price +7.5% over the past month.

Price vs Fair Value (12 months)

HK$15.30 HK$10.17 Fair Value HK$6.88 Jun 2025 Jul 2026

12‑month range HK$10.17 – HK$15.30 · fair‑value band HK$4.54 – HK$8.60 · the HK$10.96 price screens above the HK$6.88 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2251 (2251) currently trades at HK$10.96, while our model-based Fair Value estimate is HK$6.88 — implying the stock looks roughly 37.2% overvalued today. We read business quality at 56/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

Over the trailing twelve months, 2251 generated revenue of HK$173M at a net margin of -14.4%. Revenue grew 42.9% year over year. It earns a return on equity of -2.0%. The balance sheet holds a net cash position of HK$554M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$173M
Revenue growth (YoY) +42.9%
Net margin -14.4%
Return on equity -2.0%
Free cash flow −HK$21.1M FY2025
Operating margin -13.3%
More key figures
EPS (TTM) HK$-0.0200
Net cash HK$554M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

2251 reported revenue of HK$173M in FY2025 versus HK$115M in FY2021, a compound +10.7%/yr. Reported net income was −HK$25.0M in FY2025.

Revenue +10.7%/yr
FY21 HK$115M
FY22 HK$114M
FY23 HK$204M
FY24 HK$156M
FY25 HK$173M
Net income
FY21 −HK$143M
FY22 −HK$180M
FY23 −HK$133M
FY24 −HK$255M
FY25 −HK$25.0M

Is 2251 fairly valued? → Check now

Similar stocks

6 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock Price Fair Value vs Fair Value
Veeva Systems Inc VEEV $172.61 $104.16 -40%
Pro Medicus Limited PME A$161.58 A$33.82 -79%
BrightSpring Health Services, Inc BTSG $67.20 $26.39 -61%
Tempus AI, Inc TEM $48.61 $12.67 -74%
HealthEquity, Inc HQY $89.72 $54.47 -39%
M3, Inc MTHRY $5.20 $5.32 +2%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is 2251 (2251) undervalued?
As of Jul 2, 2026, our model estimates a fair value of HK$6.88 versus a price of HK$10.96 — about −37% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 2251?
Our model-based fair value for 2251 is HK$6.88 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$10.96.
What is the quality score of 2251?
2251 has a Quality Score of 56/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of 2251 (2251)?
2251 reported trailing-twelve-month revenue of about HK$173M (latest available figure, as of Jul 2, 2026).
What is the net profit margin of 2251?
The net profit margin of 2251 is about -14.4%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.